Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp. shares T.BCT are trading down $0.03 at $6.35.
Stocks in play: BriaCell Therapeutics Corp.
Baystreet - Contributor Content 
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Alphabet%20Inc_%20and%20Google%20logos%20seen%20displayed%20on%20a%20smartphone%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
/Phone%20and%20computer%20internet%20network%20by%20Pinkypills%20via%20iStock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)